Related Experiment Video
Updated: Mar 15, 2026

11:19
Isolation of Human Ventricular Cardiomyocytes from Vibratome-Cut Myocardial Slices
Published on: May 10, 2020
11.6K
Treating arrhythmias with adjunctive magnesium: identifying future research directions
European Heart Journal. Cardiovascular Pharmacotherapy
|September 17, 2016
Summary
Magnesium plays a key role in regulating heart rhythm by controlling ion channels. Further research is needed to clarify magnesium
Area of Science:
- Cardiology
- Biochemistry
- Electrophysiology
Background:
- Magnesium is a crucial intracellular cation, vital for numerous physiological processes.
- It regulates ion channel function (Na+, K+, Ca2+) in myocardial cells, influencing cardiac action potentials.
- Altered ion channel function can lead to cardiac dysrhythmias.
Purpose of the Study:
- To review the established and potential therapeutic roles of magnesium in managing cardiac arrhythmias.
- To identify limitations and gaps in the current literature regarding magnesium's efficacy and optimal use.
Main Methods:
- Literature review of existing studies on magnesium supplementation and cardiac arrhythmias.
- Analysis of clinical evidence for magnesium's effectiveness in various arrhythmia types.
- Identification of methodological limitations in previous research.
Main Results:
- Magnesium supplementation shows potential in terminating specific arrhythmias like torsade de pointes.
- It is recognized for preventing post-operative atrial fibrillation and aiding acute atrial fibrillation treatment.
- Magnesium may enhance the efficacy and safety of antiarrhythmic drugs.
Conclusions:
- Current evidence supports magnesium's therapeutic potential in cardiac arrhythmia management.
- Significant gaps remain, including unclear links between intracellular magnesium levels and clinical outcomes.
- Future research should address limitations in sample size, dosage, administration routes, and follow-up duration.
Related Concept Videos
Dysrhythmias VI: Management of Dysrhythmias
569
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
569
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
3.9K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
3.9K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
2.5K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.5K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
2.2K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.2K
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
789
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
789
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
2.8K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.8K

